NCT07058649 is a clinical trial in HCC - Hepatocellular Carcinoma, sponsored by Beijing Tsinghua Chang Gung Hospital.

Who is sponsoring NCT07058649?

NCT07058649 is sponsored by Beijing Tsinghua Chang Gung Hospital.

What condition does NCT07058649 study?

NCT07058649 studies HCC - Hepatocellular Carcinoma.

Is NCT07058649 still recruiting?

NCT07058649 is currently not yet recruiting. Last updated 10 July 2025.

Last reviewed 2025-07-10 · How we verify

NCT07058649

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Downstaging Prediction Model for HCC

Not yet recruiting Last updated 10 July 2025

What this trial tests

trial in HCC - Hepatocellular Carcinoma in 369 participants. Not yet recruiting.

Timeline

16 July 2025

Primary endpoint
1 October 2027

1 December 2027

Quick facts

Lead sponsor	Beijing Tsinghua Chang Gung Hospital
Status	Not yet recruiting
Study type	OBSERVATIONAL
Enrollment	369
Start date	16 July 2025
Primary completion	1 October 2027
Estimated completion	1 December 2027

Conditions studied

HCC - Hepatocellular Carcinoma — all drugs for HCC - Hepatocellular Carcinoma →

Sponsor

Beijing Tsinghua Chang Gung Hospital

Who can join

18 and older, any sex, with HCC - Hepatocellular Carcinoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study is a real-world, single-center study that collects imaging and clinical data from patients with HCC who are downstaged beyond the UCSF criteria.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for HCC - Hepatocellular Carcinoma

Currently open trials in the same condition.

NCT07521852 — A Phase IIa, Single-arm, Open-label Clinical Study to Evaluate the Efficacy, Safety and PK of CVM-1118 in Combination Wi · Phase 2 · recruiting
NCT07351669 — A Multicenter Prospective Study on the Performance of Spectral CT for Evaluating Treatment Response After TACE in Hepato · recruiting
NCT07310173 — Phase IIb Study of AST-3424 in Patients With AKR1C3-high Expressing Advanced Hepatocellular Carcinoma · Phase 2 · recruiting
NCT07285850 — The Efficacy of Sequential Treatment With Bevacizumab Combined With Atezolizumab in Advanced Liver Cancer With MASLD · Phase 2, PHASE3 · recruiting
NCT06999837 — [68Ga]Ga-PSMA PET/CT in Hepatocellular Carcinoma: Impact of Multiparametric Dynamic Whole-body Imaging and Kinetic Model · NA · recruiting

Other Beijing Tsinghua Chang Gung Hospital trials

Trials by the same sponsor.

NCT07123675 — AI-Assisted Blood Pressure Control During Anesthesia · NA · not yet recruiting
NCT07152496 — Host-Microbe Interactions in Biliary Dilatation · not yet recruiting
NCT07330271 — PTC-Guided Therapy for Peritoneal Mesothelioma · NA · recruiting
NCT07328737 — One vs Three HIPEC Cycles After CRS for Pseudomyxoma Peritonei · NA · recruiting
NCT07044947 — Oteseconazole in the Treatment of Adults With Vulvovaginal Candidiasis（VVC） · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT07058649 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Beijing Tsinghua Chang Gung Hospital
Last refreshed: 10 July 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07058649.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing